The combination of BRAF inhibition with downstream MEK inhibition was first shown to be of clinical value in adults with non-small cell lung cancer (NSCLC) and anaplastic thyroid cancer (60–64). Here, MAP2K7 is linked to non-small cell lung carcinoma.